Phase IV group study of natural human interferon alpha (HLBI) on chronic myelogeneous leukaemia |
| |
| Authors: | Shigeru Arimori Hideo Terada Kazuo Hayami Yoshitaka Aoyagi Shigeki Motomura Hitoshi Fukawa Noriko Akatsuka Susumu Shimizu Fumio Kodama Shozou Chiba Akio Urabe Mitsuhiro Omine Keiichi Harada |
| |
| Institution: | (1) Departments of Medicine and Hematology, Tokai University School of Medicine, Japan;(2) Departments of Medicine and Hematology, International St. Luka Hospital, Japan;(3) Departments of Medicine and Hematology, Yokohama National Hospital, Japan;(4) Departments of Medicine and Hematology, Yokosuka Mutual Aid Hospital, Japan;(5) Departments of Medicine and Hematology, Yokohama City University School of Medicine, Japan;(6) Departments of Medicine and Hematology, Yokohama Municipal Citizen's Hospital, Japan;(7) Departments of Medicine and Hematology, St. Marianna University School of Medicine, Japan;(8) Departments of Medicine and Hematology, Kanagawa Cancer Center, Japan;(9) Departments of Medicine and Hematology, Yokohama Hospital for Labor Welfare Corporation, Japan;(10) Departments of Medicine and Hematology, Teikyo University School of Medicine, Japan;(11) Departments of Medicine and Hematology, Showa University Fujigaoka Hospital, Japan;(12) Departments of Medicine and Hematology, Kawasaki Municipal Hospital, Japan |
| |
| Abstract: | Under the control of Kanagawa CML/HLBI phase IV study group in Japan, 18 cases out of registered 30 cases of chronic myelogeneous leukaemia consisting of 17 chronic phase and 1 accelerated phase, during July, 1991 to January, 1992, were analyzed for their hematological responses and cytogentic responses preliminarily. Hematological response rate (PR + CR) was 83.3% including 50.0% of CR, as judged by Kimura's criteria after treatment with HLBI alone (16 cases) or/and with other chemotherapy (2 cases). The dosage and duration of HLBI therapy required to get into the complete remission ranged from 212 to 1272 millions IU and between 6 to 42 weeks (mean value was 20 weeks), respectively. The clonally proliferated leukocytes and decreased physiological hematopoiesis started to recover from 2 to 4 weeks and reached their normal ranges from 16 weeks after 6 millions IU of HLBI were administered every day. In the 4 cases examined, 3 cases showed minimal cytogenetic responses and a case showed no cytogenetic response. Slight and temporary adverse effects were observed in 15 out of 18 cases (83.3%) including fever, general malaise, appetite loss, eruption, diarrhea, glossitis, hypogustation, weight loss and local muscle pain.Abbreviations HLBI
Human interferon alpha originated from human lymphoblastoid cell line |
| |
| Keywords: | CML interferon alpha multicenter group study remission rate side effect |
| 本文献已被 SpringerLink 等数据库收录！ |
|
